These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 11038003)

  • 21. Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma.
    Dimitrakopoulou-Strauss A; Strauss LG; Schlag P; Hohenberger P; Möhler M; Oberdorfer F; van Kaick G
    J Nucl Med; 1998 Jul; 39(7):1197-202. PubMed ID: 9669393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical development of eniluracil/fluorouracil: an oral treatment for patients with solid tumors.
    Levin J; Hohneker J
    Invest New Drugs; 2000 Nov; 18(4):383-90. PubMed ID: 11081574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral eniluracil/5-FU for advanced colon and breast carcinomas.
    Benson AB
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):57-63; discussion 64. PubMed ID: 11219979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.
    Ochoa L; Hurwitz HI; Wilding G; Cohen D; Thomas JP; Schwartz G; Monroe P; Petros WP; Ertel VP; Hsieh A; Hoffman C; Drengler R; Magnum S; Rowinsky EK
    Ann Oncol; 2000 Oct; 11(10):1313-22. PubMed ID: 11106122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
    Guo XD; Harold N; Saif MW; Schuler B; Szabo E; Hamilton JM; Monahan BP; Quinn MG; Cliatt J; Nguyen D; Grollman F; Thomas RR; McQuigan EA; Wilson R; Takimoto CH; Grem JL
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):79-85. PubMed ID: 12707718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 18F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases.
    Zissen MH; Kunz P; Subbarayan M; Chin FT; Conti PS; Fisher GA; Quon A
    Nucl Med Commun; 2011 May; 32(5):343-7. PubMed ID: 21412178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Noninvasive determination of the arterial input function of an anticancer drug from dynamic PET scans using the population approach.
    Kissel J; Port RE; Zaers J; Bellemann ME; Strauss LG; Haberkorn U; Brix G
    Med Phys; 1999 Apr; 26(4):609-15. PubMed ID: 10227363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon.
    Czito BG; Hong TJ; Cohen DP; Tyler DS; Lee CG; Anscher MS; Ludwig KA; Seigler HF; Mantyh C; Morse MA; Lockhart AC; Petros WP; Honeycutt W; Spector NL; Ertel PJ; Mangum SG; Hurwitz HI
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):779-85. PubMed ID: 14967434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
    Humerickhouse RA; Dolan ME; Haraf DJ; Brockstein B; Stenson K; Kies M; Sulzen L; Ratain MJ; Vokes EE
    Clin Cancer Res; 1999 Feb; 5(2):291-8. PubMed ID: 10037177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
    Keith B; Guo XD; Zentko S; Harold N; Schuler B; Quinn M; Shapiro J; Grem JL
    Clin Cancer Res; 2002 May; 8(5):1045-50. PubMed ID: 12006517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical development of eniluracil: current status.
    Hohneker JA
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):52-6. PubMed ID: 9830627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biochemical modulation of the catabolism and tissue uptake of the anticancer drug 5-fluorouracil by 5-bromovinyluracil: assessment with metabolic (19)F MR imaging.
    Brix G; Bellemann ME; Haberkorn U
    Magn Reson Med; 1999 Nov; 42(5):936-43. PubMed ID: 10542353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract.
    Czito BG; Hong TJ; Cohen DP; Petros WP; Tyler DS; Pappas TN; Yu D; Lee CG; Lockhart AC; Morse MA; Fernando N; Hurwitz HI
    Cancer Invest; 2006 Feb; 24(1):9-17. PubMed ID: 16466986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 5-Ethynyluracil (GW776): effects on the formation of the toxic catabolites of 5-fluorouracil, fluoroacetate and fluorohydroxypropionic acid in the isolated perfused rat liver model.
    Arellano M; Malet-Martino M; Martino R; Spector T
    Br J Cancer; 1997; 76(9):1170-80. PubMed ID: 9365165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of fluorouracil metabolite analysis in excised tumor. Lability of anabolites.
    Bading JR; Shahinian AH; Paff MT; Yoo PB; Hsia DW
    Biochem Pharmacol; 2000 Oct; 60(7):963-7. PubMed ID: 10974205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma.
    Dimitrakopoulou A; Strauss LG; Clorius JH; Ostertag H; Schlag P; Heim M; Oberdorfer F; Helus F; Haberkorn U; van Kaick G
    J Nucl Med; 1993 Jul; 34(7):1075-81. PubMed ID: 8315481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluorine-18-labeled 5-fluorouracil is a useful radiotracer for differentiation of malignant tumors from inflammatory lesions.
    Sugae S; Suzuki A; Takahashi N; Minamimoto R; Cheng C; Theeraladanon C; Endo I; Togo S; Inoue T; Shimada H
    Ann Nucl Med; 2008 Jan; 22(1):65-72. PubMed ID: 18250989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of the biodistribution and metabolism of 5-fluorouracil as monitored by 18F PET and 19F MRI: a comparative animal study.
    Brix G; Bellemann ME; Haberkorn U; Gerlach L; Lorenz WJ
    Nucl Med Biol; 1996 Oct; 23(7):897-906. PubMed ID: 8971857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of [18F]FETNIM: a potential marker for PET.
    Grönroos T; Eskola O; Lehtiö K; Minn H; Marjamäki P; Bergman J; Haaparanta M; Forsback S; Solin O
    J Nucl Med; 2001 Sep; 42(9):1397-404. PubMed ID: 11535732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of 5-diazouracil on the catabolism of circulating pyrimidines in rat liver and kidneys.
    Holstege A; Pausch J; Gerok W
    Cancer Res; 1986 Nov; 46(11):5576-81. PubMed ID: 3756903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.